TELA Bio (TELA) EBITDA Margin Growth (3y) (2021 - 2026)
TELA Bio (TELA) EBITDA Margin Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -343.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 17.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 487.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -283.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 1,505.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -763.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -184.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | TELA Bio | 40.65 Mn | 1.11 Mn | 12.52 Mn | 3,927.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,927.00 |
| Dec 31, 2025 | 4,936.00 |
| Sep 30, 2025 | 4,850.00 |
| Jun 30, 2025 | 5,341.00 |
| Mar 31, 2025 | 6,305.00 |
| Dec 31, 2024 | 4,407.00 |
| Sep 30, 2024 | 4,489.00 |
| Jun 30, 2024 | 2,483.00 |
| Mar 31, 2024 | 9,462.00 |
| Dec 31, 2023 | 4,683.00 |
| Sep 30, 2023 | 6,153.00 |
| Jun 30, 2023 | 7,581.00 |
| Mar 31, 2023 | 7,992.00 |
| Dec 31, 2022 | 3,856.00 |
| Sep 30, 2022 | 1,204.00 |
| Jun 30, 2022 | 3,181.00 |
| Mar 31, 2022 | 3,709.00 |
| Dec 31, 2021 | 13,513.00 |
| Sep 30, 2021 | 1,981.00 |